* Estimating multiplier effects (in-state), especially for non-labor, when there is no in-state activity outside of UVM!
** In particular, there are no externalities to clinical trials or federal grants because there is no one else in the state to benefit from spillovers.
* The Cancer Center proposes making UVM a top 10% 90th percentile recipient of cancer grants and accounting for perhaps 25% of all UVM NIH grants (15% of funding).
From FY 2021 to FY 2030, the research spending will add $161.6 million in